LYZ and chronic kidney disease: At last follow-up, kidney function evolution was heterogenous, with 4 patients evolving to CKD 3, 4 patients to CKD 4, and 1 patient to end-stage kidney disease, which was comparable to Belliere et al.13 Interestingly, in Gipe et al.8 study, although supportive care and cytoreductive therapy did help improve renal function in all patients with lysozyme-induced nephropathy, they continued to have CKD, potentially arguing for earlier cytoreduction and renal risk factor mitigation.